ATRC is the ticker symbol for AtriCure, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ATRC with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ATRC a good stock to buy?

13F Pro's AI ranking engine scores ATRC at 59.0/100, ranked #961 of 2,962 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for ATRC is available at https://13fpro.ai/company/ATRC. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source ATRC data?

All AtriCure, Inc. fundamentals and ownership data come directly from SEC EDGAR. AtriCure, Inc. files with the SEC under CIK 1323885. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

AtriCure, Inc.(ATRC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

AtriCure, Inc. (ATRC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATRC at 59.0/100 on a 32-signal composite quality model, placing it at rank #961 of 2,962 stocks — the top half of the AI-ranked universe. ATRC scores in the top quartile across earnings quality (97.4). Areas of concern include revenue scale (38.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AtriCure, Inc. reports quarterly revenue of $153.6M, net income of $9.0M, an operating margin of 6.3%. Top institutional holders of ATRC by reported 13-F value include BlackRock, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ATRC trades on the Nasdaq exchange and files with the SEC under CIK 1323885. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATRC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AtriCure, Inc. directly from SEC EDGAR.

AI Quality Score

59.0/100

AI Rank

#961

Revenue

$153.6M

Net Income

$9.0M

Free Cash Flow

$18.4M

Operating Margin

6.3%

ATRC key financials by period

AtriCure, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$534.5M	$-11.4M	-1.8%
FY 2024	10-K	$465.3M	$-44.7M	-8.6%
FY 2023	10-K	$399.2M	$-30.4M	-6.7%
FY 2022	10-K	$330.4M	$-46.5M	-12.9%
FY 2021	10-K	$274.3M	$50.2M	20.1%
FY 2020	10-K	$206.5M	$-48.2M	-21.4%

Institutions holding ATRC

Institutional investors reporting a position in AtriCure, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	4,474,548	$125.2M	2026-06-30
WELLINGTON MANAGEMENT GROUP LLP	3,495,603	$97.8M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	3,127,195	$87.5M	2026-06-30
Hood River Capital Management	2,905,299	$81.3M	2026-06-30
ALLIANCEBERNSTEIN L.P.	2,768,365	$79.0M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	2,190,413	$61.3M	2026-06-30
NOMURA ASSET MANAGEMENT INTERNATIONAL	1,734,279	$48.5M	2026-06-30
GOLDMAN SACHS GROUP	1,597,988	$44.7M	2026-06-30
STATE STREET	1,389,989	$38.9M	2026-06-30
MARSHALL WACE, LLP	1,333,904	$37.3M	2026-06-30